Quantitative assessment of antibiotic-responsive RNA transcripts holds promise for a 22 pump alleles acquired from commensal Neisseria, three resistant isolates with the C2611T 23s 126 rRNA mutation, and one resistant isolate with the A2059G 23s rRNA mutation (17, 18). A total 127 of ~258 million 50 bp paired-end reads were generated across 90 libraries. Each library had on 128 average 3.17 ± 0.16 million reads, and an average of 1.82 ± 0.11 million reads per library 129 mapped to the FA1090 (AE004969.1) reference genome. 130 131 Genetic distance and population structure impact transcriptome regulation 132
rapid point of care (POC) diagnostic tool for antimicrobial susceptibility testing. These assays 23 aim to distinguish susceptible and resistant isolates by transcriptional differences upon drug 24 exposure. However, an often-overlooked dimension of designing these tests is that the genetic 25 diversity within a species may yield differential transcriptional regulation independent of 26 resistance phenotype. Here, we use a phylogenetically diverse panel of Neisseria gonorrhoeae 27 and transcriptome profiling coupled with RT-qPCR to test this hypothesis, to identify 28 azithromycin responsive transcripts and evaluate their potential diagnostic value, and to evaluate 29 previously reported diagnostic markers for ciprofloxacin resistance (porB and rpmB). 30
Transcriptome profiling confirmed evidence of population structure in transcriptional response to 31 azithromycin. Taking this population structure into account, we found azithromycin-responsive 32 transcripts overrepresented in susceptible strains compared to resistant strains, and selected four 33 candidate diagnostic transcripts (rpsO, rplN, omp3, and NGO1079 ) that were the most 34 significantly differentially regulated between phenotypes across drug exposure. RNA signatures 35 for these markers categorically predicted resistance in 19/20 cases, with the one incorrect 36 categorical assignment for an isolate at the threshold of reduced susceptibility. Finally, we found 37 that porB and rpmB expression were not diagnostic of ciprofloxacin resistance in a panel of 38 isolates with unbiased phylogenetic sampling. Overall, our results suggest that RNA signatures 39 as a diagnostic tool are promising for future POC diagnostics; however, development and testing 40 should consider representative genetic diversity of the target pathogen. 41
INTRODUCTION 42
The rise of resistance to antimicrobial drugs presents a critical threat to the successful 43 treatment of infectious diseases. Rapid point of care (POC) diagnostics for drug susceptibility 44 could guide therapeutic decisions, thereby improving time to appropriate therapy and limiting the 45 extent of broad empiric antibiotic use. DNA-based susceptibility prediction tests are promising 46 and may have niche applications, but are subject to concerns about the comprehensiveness with 47 which genotypic features accurately predict resistance (i.e., due to complex epistasis or the 48 additive effects of other loci) and are also sensitive to the emergence of novel resistance alleles 49 through mutation or horizontal gene transfer. In contrast, quantitative assessment of antibiotic-50 responsive RNA transcripts can rapidly differentiate pathogen strains by resistance phenotype 51 independent of resistance mechanism or genetic background. Some of the earliest cellular 52 responses to antibiotic exposure are mediated through transcriptional changes, which has 53 recently been demonstrated in Escherichia coli, Pseudomonas aeruginosa, Klebsiella 54 pneumoniae, Acinetobacter baumannii, and Neisseria gonorrhoeae (1-4). These RNA-based 55 tests are particularly attractive as POC diagnostics as drug sensitive and resistant bacteria 56 proceed down distinct physiological pathways indicative of cellular stress or normal cell growth 57 in as little as 10 minutes (3) -much faster than the current 'gold standard' for resistance 58 phenotyping via minimum inhibitory concentration (MIC) by agar dilution, e-test, or disk 59 diffusion which can take days to months depending on bacterial growth rate. 60
Consideration of the impact of genetic diversity within the targeted pathogen species will 61 be key to the success of effective RNA-based antimicrobial resistance diagnostics. Gene 62 expression heterogeneity is known to occur between distinct lineages within bacterial species (5-63 7) , and this strain-to-strain variation leaves the open possibility that transcripts may be antibiotic-64 4 responsive in some strains but not others of the same phenotype. Thus, to identify antibiotic-65 responsive transcripts that define the resistance phenotype independent of genetic mechanism of 66 resistance and genomic background, panels of clinical isolates must be surveyed to characterize 67 the full transcriptional diversity of a species. However, while large panels of isolates have been 68 used before to search for diagnostic transcripts (1-4), lack of consideration of phylogenetic 69 structure and specific attention to diverse clade sampling within the assay design panel risks 70 mistakenly attributing distinct RNA signatures to resistance phenotype when they instead derive 71 from population structure (i.e., as a result of genetic drift or divergent selection). 72
Here, we interrogate the impact of phylogenetic distance on strain variability in gene 73 expression, and search for antibiotic-responsive RNA transcripts diagnostic of antimicrobial 74 resistance in Neisseria gonorrhoeae, the Gram-negative pathogen that causes the sexually 75 transmitted disease gonorrhea. Antimicrobial resistance in N. gonorrhoeae is one of the most 76 critical contemporary threats to public health with resistance emerging to every class of 77 antimicrobials that have been used to empirically treat gonococcal infection (i.e., penicillins, 78 sulfonamides, tetracyclines, fluoroquinolones, macrolides, and cephalosporins) (8, 9) . With 79 only a few novel antimicrobials and combination therapies currently in development (10-12) and 80 rapidly rising incidence of infection (13), we face an imminent threat of untreatable gonorrhea 81 (9, 14) . POC tests that move healthcare providers away from empiric treatment to data-driven 82 prescription are urgently needed to support good antimicrobial stewardship by rapidly dispensing 83 effective therapeutics to individuals and their sexual contacts and minimizing the selective 84 pressures on bacterial bystanders from inappropriate treatment (15). 85
We focused on RNA-based diagnostic assay development for two clinically relevant 86 drugs: azithromycin and ciprofloxacin. Azithromycin is a macrolide antibiotic that inhibits 87 5 protein synthesis by binding to the 23S rRNA component of the 50S ribosome, and is one of the 88 two first-line drugs recommended as dual-antimicrobial therapy for uncomplicated cases of 89 gonococcal infection by the U.S. Centers for Disease Control and Prevention (CDC) (16) . 90
Azithromycin resistance is especially attractive for phenotypic diagnostic development, as there 91 are multiple resistance mechanisms, including as yet unexplained pathways (17, 18) . Resistance 92 mechanisms that have been associated with or experimentally confirmed to be involved in 93 reduced susceptibility to azithromycin include: mutations in the 23S rRNA azithromycin binding 94 sites (C2611T and A2059G) (17, 19, 20) , mosaic multiple transferable resistance (mtr) efflux 95 pump alleles acquired from commensal Neisseria species (17, 18, (21) (22) (23) , mutations that enhance 96 the expression of Mtr (24-26), mutations in rplD (17), rplV tandem duplications (17), and 97 variants of the rRNA methylase genes ermC and ermB (27) . Ciprofloxacin is a quinolone 98 antibiotic that targets DNA gyrase (encoded by gyrA) and topoisomerase IV (encoded by parC), 99
and was recommended as a first-line therapy for gonorrhea until 2007, at which point the 100 prevalence of quinolone resistance overtook the 5% accepted threshold for suggested use (28). 101
However, the development of a DNA-based diagnostic for quinolone susceptibility has led to the 102 introduction of targeted quinolone use (29), and as such makes an attractive target for rapid POC 103
diagnostics. 104
Here, we used RNA-seq to profile the transcriptomes of a panel of N. gonorrhoeae 105 isolates that are representative of the known diversity within the gonococcal population (17), in 106 response to exposure to azithromycin. Using the transcriptomes from this panel, we ask: is there 107 a differential transcriptome-wide response to azithromycin between resistant and susceptible 108 isolates, what is the impact of evolutionary distance on transcriptome regulation, and are RNA 109 signatures of particular transcripts ubiquitously diagnostic of resistance phenotype across the 110 6 species? After defining candidate diagnostic markers for azithromycin resistance, we then verify 111 them via RT-qPCR in an expanded panel of isolates. We also assess the previously described 112 diagnostic markers for ciprofloxacin resistance in N. gonorrhoeae, porB and rpmB (3), in a 113 phylogenetically representative panel of isolates. 114
115

RESULTS 116
Transcription profiling 117
Whole transcriptome profiling was used to identify differentially expressed azithromycin-118 responsive RNA transcripts between resistant and susceptible isolates of N. gonorrhoeae after 60 119 and 180 minutes of below breakpoint azithromycin exposure (0.125 µg/ml; Figure 1 ). Clinical 120 isolates were sampled from across the known phylogenetic diversity of the species, based on the 121 collection reported in Grad et al. (17) . This included paired resistant (MIC ³ 1 µg/ml) and 122 susceptible (MIC < 1 µg/ml) strains from four of the twelve sub-structured clades, termed 123 Bayesian analysis of population structure (BAPS) groups (17) (Table 1; Figure 2A ). In total ten 124 isolates were selected: four susceptible isolates, two resistant isolates with mosaic mtr efflux 125 7 First, we investigated the relationship between phylogenetic structure and transcriptome 133 regulation. Principal component analysis (PCA) revealed three distinct transcriptional clusters 134 along the first two dimensions (PC1 and PC2), representing the greatest variability within the 135 gene expression dataset, which were primarily structured by genetic distance rather than 136 resistance phenotype, resistance mechanism, or drug exposure condition (Figure 2A ; Figure 2B ). 137
Isolates that belonged to BAPS groups 4 and 7, which were the most genetically similar as 138 indicated by their grouping in adjacent clades, were also the most transcriptionally similar and 139 clustered on the PCA plot ( Figure 2A ; Figure 2B ). These two clades, in addition to containing 140 susceptible isolates, harbored multiple mechanisms of resistance among resistant isolates 141 including: the 23s rRNA C2611T, 23s rRNA A2059G, and mosaic mtr efflux pump mutations. 142
Isolates from BAPS groups 6 and 8 clustered independently from each other as well as the other 143 clades sampled, and were also the most evolutionarily distant from other clades on the 144 gonococcal tree (Figure 2A ; Figure 2B ). 145
The relationship between genetic distance and transcriptional regulation was also 146 supported by a pairwise comparison of whole-genome SNP distance versus pairwise fold change 147 differences in gene expression across all ten isolates transcriptionally profiled in multiple 148 treatment conditions. SNP distances for all isolate pairs ranged from 488 to 6,106 (mean=3,410) . 149
The type of each pairwise comparison was defined as being of either the same (resistant versus 150 resistant or susceptible versus susceptible) or different (resistant versus susceptible) phenotypic 151 classes. For both categories, paired isolates of increasing core genome SNP distances had an 152 increasing number of differentially regulated transcripts (≥ 2-fold expression difference) between 153 them at baseline (T0) and in treatment conditions (T60 and T180), as indicated by each linear 154 model's positive slope values ( Figure 2C ). This pattern also held true for all transcripts 155 8 regardless of their fold change in abundance between isolates ( Supplementary Figure 1) . 156
Interestingly, at baseline (T0), the two markers previously reported as being diagnostic of 157 ciprofloxacin resistance (3), porB and rpmB, diverged transcriptionally with increasing 158 evolutionary distance between isolates as well ( Supplementary Figure 1) . 159 For susceptible isolates, we observed large-scale changes in gene expression in response 173 to azithromycin in both treatments, thus the 60-minute time point was selected for designing 174 candidate diagnostic markers. Candidate markers were required to be significantly differentially 175 expressed between the control and drug exposure in the susceptible strains and between resistant 176 and susceptible isolates under drug exposure and also to have a significant interaction term. 177
From the 413 transcripts that fit these conditions, we selected those that were within the lists of 9 the top 10% of most significant FDR-corrected P-values for each comparison to assess as 179 markers via RT-qPCR ( Supplementary Figure 2; Supplementary Figure 3 ). 180
181
RT-qPCR Validation 182
Azithromycin 183
We assessed the diagnostic potential of RNA-seq nominated markers in a large panel of 184 genetically diverse isolates with non-biased phylogenetic sampling using RT-qPCR. In addition 185 to the panel of isolates used for RNA-seq, ten more isolates were chosen from eight of the twelve 186 BAPS groups for validation (Table 1; Figure 2A ). Of these, five were susceptible, three were 187 resistant and had mosaic mtr alleles, one was resistant and had the C2611T 23s rRNA mutation, 188 and one was resistant and had a tandem duplication in rplV that has previously been associated 189 with resistance (17). We investigated the relationship between the transcriptional response of these markers to 202 azithromycin exposure and MIC by fitting a linear model to the log2-transformed 2 -DDCT and MIC 203 values, omitting the GCGS0745 outlier isolate (MIC > 256 µg/ml). For all markers there was a 204 strong negative relationship between these two variables, with r 2 values ranging between -0.79 205 and -0.89 ( Figure 3E -H). Fitted models were subsequently used to estimate the MICs of each 206 isolate given 2 -DDCT for each marker, which were then averaged across markers, and rounded to 207 the nearest MIC on the discreet scale used by the Center for Disease Control and Prevention's 208 Gonococcal Isolate Surveillance Project (GISP) clinical microbiology laboratories (32) ( Table  209 2). Using this method, RNA signatures for these markers were able to categorically predict 210 resistance in 19/20 cases, with the one susceptible isolate called as resistant predicted to be 211 within 1 dilution of the actual MIC (predicted at 1 µg/ml, phenotyped at 0.5 µg/ml), and on the 212 cusp of the reduced susceptibility phenotypic designation. Using this method, we could also 213 predict the MIC of each isolate within + or -2 dilutions of the tested MIC in 18/20 of cases. For 214 the two isolates for which MICs were incorrectly assigned, the resistance category was called 215 correctly. 216
217
Ciprofloxacin 218 For our ciprofloxacin test panel, we selected a set of isolates from the panel that had 219 previously been used to develop diagnostic markers for ciprofloxacin resistance (3) and also 220 added isolates that represented a more phylogenetically comprehensive sampling. The set of 221 isolates used for diagnostic marker development included six resistant isolates (MIC ³ 1 µg/ml) 222 with parC (S87R) and gyrA (S91F, D95G) mutations from a single BAPS clade, and five 223 susceptible isolates (MIC < 1 µg/ml) from BAPS clades located elsewhere on the tree (Table 3 ; 224 Figure 4A ). The additional isolates tested here included two resistant isolates with unknown 225 mechanisms of resistance; two resistant isolates with the ParC S87R, GyrA S91F/D95G 226 haplotype; one resistant isolate with the ParC S87R, GyrA S91F/D95A haplotype; and seven 227 susceptible isolates (Table 3 ; Figure 4A ). RNA-based resistance diagnostics have the potential to revolutionize antimicrobial 241 selection at the point of care. However, the design of diagnostic tests that rely on changes in 242 RNA-abundance after drug exposure can be vulnerable to erroneous candidate marker 243 designation due to the potential for gene regulation divergence to reflect genetic distance and 244 population structure rather than resistance phenotype. This danger can be amplified if the 245 sampling of isolates for marker design is highly phylogenetically structured by resistance 246 phenotype. Here, we used a combination of whole transcriptome profiling and RT-qPCR to test 247 12 the importance of controlling for genetic diversity in the design of RNA-based tests, to identify 248 azithromycin responsive transcripts and evaluate their potential diagnostic value, and to evaluate 249 previously reported diagnostic markers for ciprofloxacin resistance (porB and rpmB). 250
We expected that if genetic distance was the main contributor to transcriptional variation 251 between isolates, increasing genetic distance would also yield increasing differences in 252 transcriptome regulation, regardless of the resistance phenotypes of the isolates being compared 253 (see models in Supplementary Figure 5 ). Results from our principal component analysis 254 demonstrated that for our panel of diverse gonococcal isolates, divergence in transcriptional 255 profiles primarily reflected population structure, as indicated by the clustering of isolates along 256 PC1 and PC2 by phylogenetic proximity (i.e., genetic relatedness) as opposed to resistance 257 phenotype, resistance mutations present (mosaic mtr or 23s rRNA), or drug exposure condition 258 ( Figure 2B ). 259
To further investigate the importance of controlling for phenotype-specific phylogenetic 260 structure in assay design panels, we quantified the pairwise inter-strain whole-genome SNP 261 distances, as a metric of evolutionary distance, and pairwise inter-strain frequency of 2-fold or 262 greater expression differences by transcript across drug exposure conditions, as a metric of 263 transcriptional regulatory evolution ( Figure 2C ). Linear models fit to either same-or cross-264 phenotype comparisons indicated several conclusions. First, at baseline for both comparison 265 types, regressions had significant and positive slopes, and y-intercepts that were not significantly 266 different than zero ( Figure 2C T0) , supporting genetic distance as the main contributor to gene 267 expression variance between isolates in this condition. Second, after 60 minutes of azithromycin 268 exposure, though genetic distance remained the main contributor to gene expression variance in 269 the same phenotypic class comparison, for isolates of different phenotypic classes the slope was 270 13 no longer significantly different than zero and the y-intercept of 337.39 was significantly greater 271 than zero. This suggests that differences in resistance phenotype had a greater impact on gene 272 expression divergence in this condition than genetic distance ( Figure 2C T60) . Third, after 180 273 minutes of azithromycin exposure for isolates of the different phenotypic class comparison the 274 slope was again not significantly different than zero and the y-intercept of 483.10 was 275 significantly greater than zero ( Figure 2C T180) . In contrast to our principal component analysis 276 supporting the importance of controlling for phenotype-specific clade sampling bias in the assay 277 design panel, these results suggest that gene expression variance driven by differences in 278 phenotype will overwhelm any genetic distance effects, as isolates of different resistance 279 phenotypes are diverted along alternative physiological trajectories in response to drug exposure. 280
However, we suggest a measure of caution in this interpretation, as positive slope values in every 281 treatment condition for cross-phenotype comparisons indicate that some variance in gene 282 regulation is still likely driven by genetic distance effects rather than resistance phenotype alone. 283
To identify candidate diagnostic markers for azithromycin resistance, we broadly 284 sampled isolates from the N. gonorrhoeae phylogenetic tree and selected four candidate 285 diagnostic markers (rpsO, rplN, omp3, and NGO1079) . For all candidate transcripts, RNA 286 abundance increased after 60 minutes of azithromycin exposure in susceptible but not resistant 287 isolates (Fig 3) , and upregulation was consistent with gene expression results from previous drug 288 challenge studies. Macrolides induce translational stalling by binding the ribosome peptide exit 289 tunnel and inhibiting the exit of nascent proteins, which has been shown to induce the 290 upregulation of ribosomal protein-encoding transcripts (33) (34) (35) . Upregulation of the 30S and 50S 291 ribosomal protein-encoding transcripts rpsO and rplN in susceptible isolates of N. gonorrhoeae 292 therefore likely serves as a good phenotypic signature of susceptibility. The omp3 gene encodes 293 14 the major gonococcal outer-membrane protein Rmp, which (1) has been implicated in the 294 formation, stabilization, and operation of the trimeric porin structure of PorB; and (2) contains a 295 peptidoglycan-binding motif, suggesting a role in crosslinking the outer-membrane proteins to 296 the peptidoglycan and the maintenance of cell membrane integrity (36, 37) . Interestingly, the 297 Rmp protein is also upregulated after spectinomycin exposure in susceptible N. gonorrhoeae 298 isolates (38). Finally, the putative oxidoreductase NGO1079 was upregulated upon drug 299 exposure in our study. NGO1079 has previously been shown to be upregulated by the AraC-like 300 regulator MpeR, and the expression of MpeR also indirectly modulates resistance to macrolides 301 through transcriptional suppression of the repressor of the mtrCDE efflux pump (39). Though all 302 transcripts were significantly upregulated in susceptible isolates compared to resistant isolates 303 across treatment conditions, isolates with intermediate MIC values bounding the reduced 304 susceptibly threshold had some overlap in 2 -DDCT values between phenotypic groups for some 305 markers ( Figure 3C and 3D) . For all tested markers we uncovered a strong negative relationship 306 between the log2-transformed 2 -DDCT and MIC values ( Figure 3E-H) . Using regression of these 307 two variables across all tested markers, we accurately predicted resistance category in 19/20 308 cases (Table 2) , with the one susceptible isolate called as resistant on the boarder of the reduced 309 susceptibility phenotypic designation (predicted at 1 µg/ml, phenotyped at 0.5 µg/ml). Though 2 -310 DDCT values could not perfectly predict resistance for isolates with intermediate MICs, results are 311 promising and continued optimization of the assay conditions (markers, drug concentration, 312 exposure time, etc.) may increase diagnostic accuracy. 313
The sampling scheme for the assay design panel isolates used to identify the transcripts of 314 porB and rpmB as diagnostic for ciprofloxacin resistance (3) had a clade bias, with all resistant 315 isolates from a single clade and all susceptible isolates from outside this clade ( Fig 4A) . 316 15 Additionally, transcription of porB and rpmB was clearly impacted by evolutionary distance in 317 control conditions (Supplementary Figure 1B) . We confirmed that porB and rpmB could 318 diagnosis resistance phenotype after 10 minutes of ciprofloxacin exposure in a set of the isolates 319 used in the prior study ( Figure 4B,C) . However, in evaluation of a broader diversity of the 320 gonococcal population, the markers no longer showed diagnostic potential, displaying 321 overlapping 2 -DDCT values between resistant and susceptible isolates (Fig 4 B,C) . These results 322 suggest that the differential expression patterns of porB and rpmB are largely independent of 323 resistance phenotype. 324
To our knowledge, our study is the first to comprehensively consider the genetic diversity 325 of a species in development of RNA-based candidate diagnostic markers for resistance 326 phenotype, and is also the first study to nominate RNA signatures diagnostic for azithromycin 327 resistance in N. gonorrhoeae. Overall, our results emphasize the power and potential of these 328 types of tests and also indicate the importance of selecting appropriate strains for the assay 329 design panel in the research and development phase. We suggest that strain design panels must 330 capture the genetic diversity of species for accurate evaluation of the factors underlying strain-to-331 strain gene expression heterogeneity, and control for the impact of phylogenetic structure on 332 phenotypic diagnostics. IsoVitaleX (Becton Dickinson Co., Franklin Lakes, N.J.). After inoculation, plates were 341 incubated at 37°C in a 5% CO2 atmosphere incubator for 16-18 hours. All isolate stocks were 342 stored at -80°C in trypticase soy broth containing 20% glycerol. Isolates for both azithromycin 343 and ciprofloxacin test panels were selected to be representative of the known diversity within the 344 gonococcal population. Antimicrobial susceptibility testing was conducted using E-test strips 345 (40) or the agar dilution method (32), and MICs were recorded after 24 hours of growth. The 346
European Committee on Antimicrobial Susceptibility Testing (EUCAST) defines azithromycin 347 reduced susceptibility as MICs ³ 1 µg/ml (41) while GISP uses a breakpoint of ³ 2 µg/ml (32). 348 Therefore, we conservatively define azithromycin reduced susceptibility in this study by the 349 EUCAST standard of ³ 1 µg/ml. For ciprofloxacin resistance we adhere to the GISP and CLSI 350 breakpoint of ³ 1 µg/ml (32, 42) , which was also the breakpoint used by Khazaei et al. (3) . 351
352
Experimental Design 353
Cells harvested from overnight plates were suspended in GCP (7.5 g Protease peptone #3, 354 0.5 g soluble starch, 2 g dibasic K2HPO4, 0.5 g monobasic KH2PO4, 2.5 g NaCl, ddH2O to 500 355 ml; Becton Dickinson Co., Franklin Lakes, N.J.) supplemented with 1% IsoVitaleX and 0.042% 356 sodium bicarbonate, and incubated at 37°C for 2 hours to mid-log phase. For azithromycin, 357 samples were collected before exposure to azithromycin, 60 minutes post 0.125 µg/ml 358 azithromycin exposure, and 180 minutes post 0.125 µg/ml azithromycin exposure (Figure 1) . For 359 ciprofloxacin we replicated the sampling scheme of Khazaei et al. (3) , and sampled paired 0.5 360 µg/ml ciprofloxacin exposed and unexposed cultures 10 minutes post drug treatment 361 ( Supplementary Figure 3) . RNA was isolated using the Direct-Zol kit with DNase I treatment 362 (Zymo Research, Irvine, C.A.) . 363
364
RNA Preparation and Sequencing 365
RNA libraries were prepared at the Broad Institute at the Microbial 'Omics Core using a 366 modified version of the RNAtag-seq protocol (43). 500 ng of total RNA was fragmented, 367 depleted of genomic DNA, dephosphorylated, and ligated to DNA adapters carrying 5'-AN8-3' 368 barcodes of known sequence with a 5' phosphate and a 3' blocking group. Barcoded RNAs were 369 pooled and depleted of rRNA using the RiboZero rRNA depletion kit (Epicentre, Madision, 370 W.I.). Pools of barcoded RNAs were converted to Illumina cDNA libraries in 2 main steps: (i) 371 reverse transcription of the RNA using a primer designed to the constant region of the barcoded 372 adaptor with addition of an adapter to the 3' end of the cDNA by template switching using 373 SMARTScribe (Clontech, Mountain View, C.A.) as described (44); (ii) PCR amplification using 374 primers whose 5' ends target the constant regions of the 3' or 5' adaptors and whose 3' ends 375 contain the full Illumina P5 or P7 sequences. cDNA libraries were sequenced on the Illumina 376 Nextseq 500 platform to generate 50-bp paired end reads. 377
378
RNA-seq Analysis 379
Barcode sequences were removed, and reads were then aligned to the FA1090 reference 380 genome (AE004969.1) using BWA v.0.7.8 (45), mapping to the sense strand of the coding 381 domain sequences (CDSs, n=1894). Differential expression analysis was conducted with 382
DESeq2 v.1.10.1, which employs an empirical Bayes method to estimate gene-specific 383 biological variation (46). A multi-factor analysis was used to account for the effects of resistance 384 18 phenotype (P), condition (C), or the interaction between both phenotype and condition on 385 transcript expression (E), using the model: 386
Per-gene dispersions were estimated using the Cox-Reid profile-adjusted method and a negative 390 binomial generalized log-linear model was fit to identify significantly differentially expressed 391 transcripts. Subsequently, gene lists were corrected for multiple testing using a false discovery 392 rate (FDR) (cut-off of ≤0.01). We then compared significant model factors to define expression 393 profiles for each transcript. 394
Genomic read libraries were obtained from the NCBI's Short Read Archive (project 395 PRJEB2090) and the European Nucleotide Archive (projects PRJEB2999 and PRJEB7904). 396
Pairwise SNP distances were generated by mapping read libraries to the FA1090 (AE004969.1) 397 reference genome using BWA v.0.7.8, and calling variants with Pilon v1.16 (47) using mapping 398 qualities > 40 and coverage depths > 5x set as minimum thresholds. SNP distance between each 399 isolate pair was then calculated excluding gaps using custom scripts. Normalized transcript read 400 counts were generated for coding domain regions annotated in the FA1090 reference for each 401 isolate (see above), and the absolute log-fold change was calculated by comparing transcriptional 402 counts per CDS between each isolate pair at baseline (no drug exposure). CDS regions with zero 403 counts in any isolate within each pair were excluded. 404
405
RT-qPCR Validation 406
19 SuperScript IV reverse transcriptase (Thermo Fisher Scientific, Waltham, M.A.) was 407 used to convert isolated RNA to cDNA using random hexamer primers. Annealing of primers to 408 the template RNA was conducted in 13 µl reactions (3.8 µM primers, 1.3 mM dNTP mix, and 409 500 ng RNA) by heating the RNA-primer mix to 65 °C for 5 minutes and then incubating on ice 410 for 1 minute. For reverse transcription, 4 µl of 5x SSIV Buffer, 1 µl of 100mM DTT, 1 µl of 411
RNaseOUT, and 1 µl of SuperScript IV reverse transcriptase were added to the reaction mix and 412 incubated at 23°C for 10 minutes, followed by 55°C for 10 minutes, and 80°C for 10 minutes. 413
Primers for azithromycin susceptibility diagnostic markers were designed to amplify 414 ~100-bp fragments of both control and target genes (Supplementary Table 1 ). The control gene 415 NGO1935 was empirically defined from our RNA-seq results, and was required to have no 416 significant change in expression across treatments for all isolates tested. Primers for 417 ciprofloxacin diagnostic markers were obtained from Khazaei et al. (3) (Supplementary Table 1) . 418
Real-time PCR was conducted with the Applied Biosystems PowerUp SYBR Green Master Mix 419 on the Applied Biosystems ViiA 7 Real-Time PCR system (Thermo Fisher Scientific, Waltham, 420 M.A.), using the following cycling conditions: 10 minutes at 95 °C, followed by 40 cycles of 95 421 °C for 15 seconds and 60-64 °C for 1 minute (see Supplementary Table 1 for primer-specific 422 details). The 6.25 µl PCR reaction mix consisted of 1 µl of 1:100 diluted cDNA, 0.5x SYBR 423
Green master mix, and 0.5 µM of the forward and reverse primer pair. Reactions were performed 424 in 384-well plates with 3-4 biological replicates per isolate tested per antibiotic exposure 425 condition. CT values were calculated using the ViiA 7 Software, and fold change was calculated 426 using the 2 -DDCT method (30, 31) . response occurred (1) in susceptible strains between the control and the drug exposed conditions, 458
(2) between resistant and susceptible isolates in the antibiotic exposure condition, and (3) variance in gene expression can be attributed to genetic distance between isolates rather than 476 drug exposure, resistance phenotype, or resistance mechanism. (C) We further tested the impact 477 of evolutionary distance on transcriptional regulation, by comparing the number of pairwise SNP 478 23 differences with the frequency of transcripts with a ≥2 fold expression difference across the ten 479 isolates for which we had collected RNA-seq data at baseline (T0, no drug exposure), after 60 480 minutes of drug exposure (T60), and after 180 minutes of drug exposure (T180). Linear models 481 were fit to either paired isolate comparisons that belonged to the same (resistant vs. resistant normalizing to an empirically defined control transcript (NGO1935, etfB). All four markers 490 showed significant differences in expression across conditions between resistant and susceptible 491 isolate phenotypic classes, however fold change for omp3 and rplN did overlap between 492 phenotypes for isolates with azithromycin MIC values close to the reduced susceptibility 493 threshold (i.e., 0.25, 0.5, 1, and 2 µg/ml). (E-H) Linear models were fit to log transformed 2 -DDCT 494 24 and MIC values for each marker for each isolate, omitting the GCGS0745 outlier (MIC > 256 495 µg/ml), and were used to assess the accuracy of 2 -DDCT values as a predictor of MIC (Table 2) a=8.92e-05; b=5.39e-01; r 2 =0.06 a=2.01e-04**; b=7.52e-02; r 2 =0.37 a=2.39e-04**; b=-6.21e-02; r 2 =0.56
a=9.01e-05; b=4.84e-01; r 2 =0.08 a=1.71e-04***; b=3.42e-01***; r 2 =0.09 a=0.00012***; b=0.55***; r 2 =0.07
a=2.82e-04***; b=3.36e-01***; r 2 =0.17 a=3.15e-05***; b=1.18***; r 2 =0.003 a=1.43e-04***; b=7.03e-01***; r 2 =0.05 a=5.50e-05***; b=1.38***; r 2 =0.007
Supplementary Figure 5 . Contrasting the impacts of phenotypic class or genetic distance as 563 the main dimension in driving transcriptional regulation. Here, we hypothesize that there are 564 two major dimensions that may drive the majority of variance in transcriptional regulation 565 between isolates: either phenotypic class (drug resistant vs. susceptible), or evolutionary time. 566 (A) Given a phylogeny of a hypothetical population with branches indicating evolutionary 567 distance and colors representing resistant (red) and susceptible isolates (blue): (B) if resistance 568 phenotype is the major component driving transcriptional variation, isolates will transcriptionally 569 cluster by phenotype as they are physiologically responding to the environment in the same way, 570 and (C) regardless of the genetic distance of isolates, paired comparisons of isolates of the same 571 phenotypes will show very little differences in transcriptional regulation, and paired comparisons 572 of isolates of different phenotypes will display greater divergence in regulation of their 573 transcriptomes. (D,E) If genetic distance is the major factor impacting transcriptional regulation, 574
we expect that with increasing evolutionary time isolates will display increasing levels of 575 differential transcriptome regulation. 576 
